The European Commission approves Regeneron Pharmaceuticals ' (NASDAQ: REGN ) Eylea (aflibercept) for the treatment of visual impairment caused by diabetic macular edema (DME). The new indication complements
appearances may be deceiving. Regeneron Pharmaceuticals , Inc . (NASDAQ: REGN ) is in my view that sort ..... hence. This article evaluates REGN using a sum-of-the-parts ..... pinpoint yet. Introduction : Regeneron is a world-class developer
Regeneron Pharmaceuticals (NASDAQ: REGN ) Q2 2014 Earnings Call August 05, 2014 8:30 am ET Executives ..... Ex Officio Member of Technology Committee and President of Regeneron Research Laboratories Robert J. Terifay - Senior Vice President
(Adds details on experimental cholesterol drug, updates shares)
colorectal cancer trials, Regeneron 's oncology drug Zaltrap ..... of its high cost. Eylea is on track to capture ..... acquisition down the road. Regeneron 's prolific monoclonal ..... 6 million in 2012. Regeneron Pharmaceuticals discovers, develops ..... marketed products: Eylea , approved for wet
The following audio is from a conference call that will begin on August 05, 2014 at 08:30 AM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Aug 5 (Reuters) - Regeneron Pharmaceuticals Inc on Tuesday reported quarterly sales above expectations on surging demand for its Eylea treatment for macular degeneration, the leading cause of blindness in the elderly.
Regeneron Pharmaceuticals (NASDAQ: REGN ): Q2 EPS of $2.47 beats by $0.18 . Revenue of $666M (+45.5% Y/Y) beats by $18.01M . Press Release Post your comment!
Regeneron reported second-quarter results that ..... better than anticipated, with U.S. Eylea sales rebounding strongly after a sluggish ..... first-quarter results. Rest of world Eylea sales, as reported by partner Bayer ..... Despite higher SG&A costs related to Eylea 's commercialization and increased ..... hypercholesterolemia patients. Importantly, Regeneron also disclosed that in a prespecified
Regeneron Pharmaceuticals (NASDAQ: REGN ) and partner Sanofi (NYSE: SNY ) ( OTCQB:SNYNF ) report that their PCSK9 inhibitor alirocumab met its primary endpoint of